EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer

Yiyue Xu, Taotao Dong, Butuo Li, Jinming Yu, Linlin Wang iD

Journal of Chemical Information and Modeling · 10.08.2026 · 66 (15) · 8893-8907

DOI: 10.1021/acs.jcim.6c01061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, online erschienen am 22.07.2026. Verfasst von Yiyue Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Deep Learning, Antineoplastic Agents, Drug Discovery. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. The absence of effective targeted therapies and endocrine treatment options leads to limited therapeutic options, which remains one of the major clinical challenges in TNBC management. Drug discovery is typically a lengthy and costly process that could be significantly improved through drug repurposing. However, the biological complexity and insufficient repurposing strategies hinder the reuse. This study aims to develop a deep learning-based framework to accelerate drug discovery for TNBC, identify novel therapeutic candidates, and uncover potential drug targets. We developed a deep neural network framework to predict the anticancer efficacy, toxicity profiles, and structural similarities of compounds. By applying this platform to screen over 6,000 compounds from the Drug Repurposing Hub, we identified promising candidates with potential therapeutic efficacy and safety profiles against TNBC. The top-predicted compounds were subsequently validated through comprehensive in vitro and in vivo functional assays. Furthermore, we employed transcriptomic sequencing and mass spectrometry-based proteomics to elucidate the molecular mechanisms underlying the anti-TNBC activity. We identified emodepside, a structurally unique molecule diverging from conventional anticancer agents that exhibited potent antitumor efficacy across multiple TNBC cell lines. Significantly, emodepside administration (5 mg/kg) inhibited tumor growth in xenograft models. Integrated multiomics analyses (RNA-seq/CETSA-MS) identified NAMPT as the primary target. This study demonstrates the viability of our deep learning models to discover structurally novel anticancer agents that are distinct from conventional drugs, thereby expanding the therapeutic arsenal for TNBC patients. Emodepside emerges as a promising TNBC therapeutic candidate, with a possible mechanism of promoting TNBC cell apoptosis via NAMPT inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDeep LearningAntineoplastic AgentsDrug DiscoveryHumansCell Line, TumorAnimalsFemaleMice

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong250117, China.
  • Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong250012, China.

ORCID-Profile: Linlin Wang

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Shandong Province
  • Key Technologies Research and Development Program
  • National Science and Technology Major Project
  • Post-Marketing Clinical Research Special Project on Innovative Drugs
  • Collaborative Academic Innovation Project of Shandong Cancer Hospital

Zitieren

APA

Xu, Y., Dong, T., Li, B., Yu, J., & Wang, L. (2026). Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer. Journal of Chemical Information and Modeling, 66(15), 8893-8907. https://doi.org/10.1021/acs.jcim.6c01061

Vancouver

Xu Y, Dong T, Li B, Yu J, Wang L. Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer. Journal of Chemical Information and Modeling. 2026;66(15):8893-8907. doi:10.1021/acs.jcim.6c01061

BibTeX
@article{Xu2026,
  author = {Xu, Yiyue and Dong, Taotao and Li, Butuo and Yu, Jinming and Wang, Linlin},
  title = {Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer},
  journal = {Journal of Chemical Information and Modeling},
  year = {2026},
  volume = {66},
  number = {15},
  pages = {8893--8907},
  doi = {10.1021/acs.jcim.6c01061}
}
Kostenlos starten →